Phenotypes of 11β-HSD1/2 and glucocorticoid receptor genetically modified mouse models in ageing related skeletal diseases
Genetic model | Cre promoter | Cells targeted | Age/Sex studied | Phenotype | Reference |
---|---|---|---|---|---|
Osteoporosis | |||||
11β-HSD2 transgenic (C57BL/6) | Osteocalcin gene 2 (OG2) | Mature osteoblasts and osteocytes | 21 months males and females | Vertebrae: higher BMD, cancellous BV, BFR and greater compression strength.Femur: higher BMD and bending strength.Osteoblast and osteocyte apoptosis reduced.Protected from age-related deteriorations in bone vasculature. | [73] |
11β-HSD2 transgenic (CD-1) | 2.3kb Pro-a1(I) collagen (Col1a1) | Osteoblasts and osteocytes | 12 and 18 months males and females | Vertebrae: females displayed higher trabecular thickness, but no change in BV/TV in either gender.18-month-old mice protected from fat accumulation, and insulin and leptin resistance. | [91] |
GR KO (C57BL/6) | Osterix (Osx) | Osteoblast progenitor cells (plus hypertrophic chondrocytes) | 21 months females | Femur: reduced femoral cortical bone area and trabecular bone mass.Serum markers of bone formation (PINP) and resorption (TRAcP5b) reduced. | [98] |
Sarcopenia | |||||
11β-HSD1 KO (C57BL/6) | Myogenic differentiation 1 (MyoD) | Myogenic progenitor cells | 22 months males | Increased muscle mass and strength. | [108] |
11β-HSD1 over-expressing(C57BL/6) | Global | All cells | 2 months males | Glucocorticoid overexpression induced muscle atrophy. | [108] |
GR KO (C57BL/6) | Skeletal muscle actin (ACTA1) | Striated myofibers | 20 weeks old males and females | Increased muscle mass.Diurnal variation and fasting-dependent temporal elevation of plasma alanine levels reduced.Lipolysis increased in adipose tissue. | [109] |
GR KO(FVB/Balb/c) | Muscle creatine kinase (MCK) | Striated and cardiac myofibers | 3–4 months females | Increased muscle mass.Protected from glucocorticoid-induced muscle atrophy.Attenuated expression of atrophy related genes (MuRF1 and MAFbx, 4E-BP1, and MT2) induced by nutritional deprivation.No effect on muscle atrophy induced by denervation. | [110] |
GR KO (C57BL/6) | Myosin light chain 1F (Mlc1f) | Striated myofibers | 12 weeks old males | Attenuated muscle atrophy. Reduced expression of proteolysis-associated genes induced by reduced food intake. | [112] |
Osteoarthritis | |||||
11β-HSD2 transgenic (CD-1) | 2.3kb Pro-a1(I) collagen (Col1a1) | Osteoblasts and osteocytes | 26 and 38 weeks old males | In young mice, no change in cartilage loss, subchondral bone sclerosis and osteophyte formation.In aged mice, cartilage loss, subchondral bone sclerosis, and osteophyte size were reduced. No changes in synovial inflammation. | [3] |
GR KO (C57BL/6) | Pro-a1(II) collagen (Col2a1)-tamoxifen inducible Cre (Cre-ERT2) | Chondrocytes | 24, 26, 30, and 38 weeks old males | Less severe cartilage loss (all timepoints) and reduced synovial inflammation (at 24 weeks).Decreased chondrocyte and synoviocyte hypoxia inducible factor (HIF)-2α expression.Reduced chondrocyte senescence and catabolic signaling.No change in subchondral bone sclerosis and osteophytes. | [128] |
GR: glucocorticoid receptor; 11β-HSD1/2: 11β-hydroxysteroid dehydrogenase types 1 and 2; KO: knockout; Cre: cre recombinase; BMD: bone mineral density; BV: bone volume; BFR: bone formation rate; BV/TV: bone volume/tissue volume; Cre-ERT2: cre fused with a mutated ligand-binding domain of estrogen receptor that is tamoxifen inducible; PINP: procollagen type I N-propeptide; TRAcP5b: tartrat-resistant acid phosphatase 5b; MuRF1: muscle RING-finger protein-1; MAFbx: muscle atrophy F-box; 4E-BP1: eukaryotic translation initiation factor 4E-binding protein 1; MT2: metallothionein 2; HIF-2α: hypoxia inducible factor 2α; kb: kiloba
EM: Conceptualization, Writing—original draft, Writing—review & editing. HZ: Writing—review & editing. MJS: Writing—review & editing. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
The authors would like to acknowledge the ongoing research support by the National Health and Medical Research Council (NHMRC) of Australia through NHMRC Ideas [APP2028787] and NHMRC Investigator [APP1196062] grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2024.